| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Definium Therapeutics, Inc. (DFTX) have been net sellers, shedding 81,951 shares worth roughly $3.0M on balance.
DFTX sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 2.21M | $80.93M | - | |
| Other | 792.8K | $28.99M | - | |
| Other | 494.2K | $18.07M | - | |
| CFO | 394.5K | $14.43M | - | |
| Other | 359.0K | $13.13M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Barrow Robert | Chief Executive Officer | Sell | 29,208 | $45.03 | $1,315,236.24 | -2.6% | -15.9% | - | |
| Mar 25, 2026 | Sullivan Mark | Chief Legal Officer | Sell | 10,702 | $18.47 | $197,665.94 | -3.8% | +95.9% | - | |
| Mar 25, 2026 | Barrow Robert | Chief Executive Officer | Sell | 24,431 | $18.47 | $451,240.57 | -3.1% | +95.9% | - | |
| Mar 25, 2026 | Karlin Daniel | Chief Medical Officer | Sell | 8,018 | $18.47 | $148,092.46 | -1.9% | +95.9% | - |